ClinicalTrials.gg
TerminatedNCT02786979Updated Jun 21, 2016

Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

A Phase 4 interventional study of Beraprost and Aspirin in Type 2 Diabetes Mellitus, sponsored by Astellas Pharma Inc. Terminated at 6 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-21.

Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Prevention

Why this study was terminated
Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing aspirin in Diabetes Mellitus, Type 2 — 1 open to participants now, 4 under way, none of them phase 3. Aspirin · Diabetes Mellitus, Type 2.

Enrollment
6th of 15
190 · median 80
Started
2010
with 2 others
Phase 4
9 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
Astellas Pharma Inc

Among the 15 studies testing aspirin in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 15 studies testing aspirin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing aspirin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • Arteriosclerosis
  • beraprost
  • Aspirin
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as type 2 diabetes mellitus;
  • Patients who had the intima-media thickness (IMT) of carotid artery ≥1.1 mm in at least one side;
  • Patients who had results of , alanine aminotransferase, and serum creatinine no more than 1.5 times higher than the ;
  • Patients who had not cardio or cerebral vascular events within 3 months, including non-fatal myocardial infarction, stable and unstable angina pectoris, and non-fatal cerebral ischemic and hemorrhagic stroke;
  • Patients who had their systolic blood pressure \<160 mmHg, diastolic blood pressure \<100 mmHg, and (HbA1c) \<8.0%;
  • Patients who had not taken any medications with antithrombotic and antiplatelet effect within 3 months;

Exclusion criteria

Exclusion Criteria:

  • Patients who had peptic ulcer or active alimentary tract hemorrhage;
  • Patients who had a known allergy to prostacycline or non- medications;
  • Patients who were pregnant, breast feeding, or had planned to be pregnant;
  • Patients who were attending or had attended any clinical studies within 3 months;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Beraprost sodium tablet and Aspirin combination group

    Oral

    Drug: Beraprost · Drug: Aspirin

  • Experimental
    Aspirin Group

    Oral

    Drug: Aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in carotid intima-media thickness

    Time frame: Baseline to Year 3

  2. Incidence and severity of treatment-emergent adverse events

    Time frame: Up to 3 years

  3. Safety assessed by vital signs: body temperature

    Time frame: Up to 3 years

  4. Safety assessed by vital signs: pulse rate

    Time frame: Up to 3 years

  5. Safety assessed by vital signs: respiratory rate

    Time frame: Up to 3 years

  6. Safety assessed by vital signs: blood pressure (systolic blood pressure and diastolic blood pressure)

    Time frame: Up to 3 years

  7. Number of participants with abnormal laboratory values and/or adverse events related to treatment

    Time frame: Up to 3 years

Secondary outcomes

  1. Death rate

    Time frame: Up to 3 years

  2. Incidence of any vascular event

    Vascular events include sudden death, death caused by the vascular event, non-fatal coronary hear disease (CHD), non-fatal cerebrovascular diseases, and non-fatal aorta and peripheral artery disease (PAD)

    Time frame: Baseline to Year 3

  3. Change from baseline in Ankle-brachial index

    Time frame: Baseline to Year 3

  4. Change from baseline in Pulse wave velocity

    Time frame: Baseline to Year 3

  5. Change from baseline in Oxidative stress indices

    Oxidative stress indices: superoxide dismutase and nitrotyrosine

    Time frame: Baseline to Year 3

  6. Change from baseline in value of VCAM-1

    VCMA-1: vascular cell adhesion molecule

    Time frame: Baseline to Year 3

  7. Change from baseline in value of TNF-α

    TNF: tumor necrosis factor

    Time frame: Baseline to Year 3

07

Study locations

6 sites
  • Site CN00001
    Beijing, Beijing, China
  • Site CN00002
    Beijing, Beijing, China
  • Site CN00004
    Guangzhou, Guangdong, China
  • Site CN00003
    Shanghai, Shanghai, China
  • Site CN00005
    Chengdu, Sichuan, China
  • Site CN00006
    Tianjin, Tianjin, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2016
First posted
Jun 1, 2016
Start
Jul 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Last update
Jun 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02786979
Responsible party
Sponsor
First posted
Jun 1, 2016
Start date
Jul 2010
Primary completion
Jan 2013
Completion
Jan 2013
Last update
Jun 21, 2016

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion